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Abstract
Background Overproduction of vascular endothelial
growth factor (VEGF) in atopic dermatitis (AD) lesions has
previously been observed. It is also known that platelet is
an important source of VEGF and platelet factor 4 (PF-4), a
potential marker of AD severity.
Aim To evaluate concentrations of VEGF and its soluble
receptors (sVEGF-R1 and sVEGF-R2) in the plasma of AD
patients and to examine its possible correlation with dis-
ease severity and plasma concentrations of PF-4, a platelet
activation marker.
Methods Plasma concentrations of VEGF and its recep-
tors and levels of PF-4 were measured by an
immunoenzymatic assay in 51 AD patients and in 35
healthy non-atopic controls. The severity of the disease was
evaluated using the eczema area and severity index.
Results AD patients showed significantly increased
VEGF and PF-4 plasma concentrations as compared with
the controls. Plasma concentrations of sVEGF-R1 and
sVEGF-R2 did not differ between the groups. There were
no remarkable correlations between plasma VEGF
concentration and disease severity or between VEGF and
PF-4 concentration.
Conclusions This study shows that plasma concentration
of VEGF may be increased in patients suffering from AD.
It seems that plasma VEGF concentration is not a useful
marker of disease severity and, apart from platelets, other
cells might also release the cytokine.
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin
disease which results from interaction of skin barrier
defects, Th1/Th2 cells dysregulation, and environmental
factors. Histologically, it is characterized by dilated vessels
and perivascular edema leading to erythema and edema [1].
Interestingly, based on the mouse model of AD, it has been
observed that angiogenesis is the major pathologic feature
of the disease [2]. It has also been suggested that mast cells
in AD may stimulate neoangiogenesis via the release of
proangiogenic factors [3]. It is known that the key role in
vascular permeability, vasodilation and angiogenesis is
played by vascular endothelial growth factor (VEGF) [4]. It
may also stimulate inflammatory cell recruitment, enhance
antigen sensitization and appear crucial for adaptive T(H)2
inflammation [5]. There are few data available on the role
of VEGF in AD. Zhang et al. [6] demonstrated increased
production of VEGF in AD lesions. Zablotna et al. [7]
suggested an association between the –1154 VEGF gene
polymorphism and AD. Therefore, the objective of our
study was to evaluate concentrations of VEGF and its
soluble receptors (sVEGFR1 and VEGFR2) in plasma of
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patients with AD and to examine their possible correlation
with disease severity. Because platelets are important
sources of VEGF, we assessed the relationship between
plasma concentrations of platelet factor 4 (PF-4), a platelet
activation marker, and this cytokine.
Methods
Patients
Fifty-one patients who fulfilled the AD criteria as defined
by Rajka and Langeland [8] were enrolled into the study.
Their clinical and laboratory baseline characteristics are
shown in Table 1. The patients were examined during the
active period of the disease. Disease severity was assessed
according to the eczema area and severity index (EASI)
scoring system [9]. The majority of the patients (33) also
suffered from persistent allergic rhinitis without any
asthma symptoms. The remaining patients suffered from
AD without any other atopic diseases such as asthma,
rhinitis or conjunctivitis. All the patients were sensitized to
house dust mite (HDM) allergens; positive skin tests to HDM
(Dermatophagoides pteronyssinus and/or Dermatophagoides
farinae) extracts and positive serology (specific IgE = class 2
or higher). They also showed positive skin prick tests to other
inhalant and food allergens which, however, were not clini-
cally significant.
The patients were not treated with any antihistamines,
topical steroids or calcineurin inhibitors for at least 1 week
before enrolment into the study (only emollients were
applied). They were free of any systemic steroids during
the preceding 8 weeks.
The patients were compared with 35 healthy non-atopic
subjects (20 males, 15 females) aged 18–38 years (median
21 years). None of the subjects had any other concomitant
dermatological or medical disorders.
All the subjects submitted respective written consent
and the study was approved by the University Committee
of Ethics.
Blood samples and analytical methods
Because platelets are a potential source of PF-4 and VEGF,
we measured VEGF concentration in platelet-poor plasma
(PPP). Blood was obtained in the morning (07:00 to 08:00,
in the fasting state) after a 25-min rest at slight or no stasis
from the antecubital vein into CTAD tubes containing four
anticoagulants—sodium citrate, theophylline, adenosine
and dypiridamole (Vacutainers, Becton–Dickinson) to
obtain maximal stabilization of platelets, then placed into
an ice/water bath. The tubes were then centrifuged at
3,0009g for 15 min at 4 C. Following the first centrifugal
cycle three-quarters of the top plasma was removed with a
plastic transfer pipet. This plasma was centrifuged again at
3,0009g for 15 min to remove the residual platelets. The
plasma obtained was stored at -70 C until assayed for
VEGF and PF-4.
Measurement of PF-4 concentration in PPP was per-
formed to assess the degree of platelet activation in vivo.
sVEGF-R1 and sVEGF-R2 concentrations were per-
formed in the plasma collected using EDTA as an
anticoagulant.
VEGF analysis
VEGF plasma concentrations were determined using the
Quantikine Human VEGF enzyme-linked immunosorbent
assay (ELISA) (R&D Systems Inc., Minneapolis, MN,
USA), to recognize the soluble isoforms (VEGF121 and
VEGF165). The detection limits were 9.0 pg/ml. Values
\9 pg/ml were equalized to zero.
sVEGF-R1 and sVEGF-R2 analyses
The receptor plasma concentrations were assayed by spe-
cific commercially available ELISA assay kits (Quantikine;
Table 1 Clinical and laboratory characteristic of AD patients
Parameters AD whole group
N 51
Sex (F/M) 29/22
Age (range; years) 23 (18–35)





Total IgE (IU/ml) (range) 522 (153–3,350)
IgE anti-Der p (IU/ml) (range) 8.37 (1.2–48.2)
IgE anti-Der f (IU/ml) (range) 11.22 (1.1–50)
SPT positive
House dust mites* 51 (100 %)
Animal dander 24 (47.05 %)
Moulds 6 (11.76 %)
Trees 19 (37.25 %)
Grasses 33 (64.70 %)
Weeds 14 (27.45 %)
Foods 6 (11.76 %)
Data are presented as median and range
N number of patients, AD atopic dermatitis, PAR persistent allergic
rhinitis, SPT skin prick tests, Der p Dermatophagoides pteronyssinus,
Der f Dermatophagoide farinae, IgE immunoglobulin E
* Der p and Der f
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R&D Systems Inc.) in accordance with the manufacturer’s
instructions. The sensitivity of the assay for VEGF-R1 and
sVEGFR-2 was 3.0 and 5 pg/ml, respectively.
PF-4 analysis
The PF-4 concentration was measured in the PPP by
ELISA using commercial Asserachrom (Diagnostica
Stago, France). The detection limit was 0.25 IU/ml.
Skin prick tests
Allergic status was evaluated using a panel of common
inhalants and the main food allergens (Allergopharma,
Reinbeck, Germany). The skin wheal-flare reaction was
read after 15 min and considered positive if the wheal
diameter was at least 3 mm larger than one formed by the
control substance.
Other laboratory investigations
The serum levels of total immunoglobulin E (IgE) and
specific IgE to D. farinae and D. pteronyssinus were
measured by ELISA using a commercial kit (Allergo-
pharma) according to the manufacturer’s instructions. The
blood platelet and eosinophil counts were determined using
an automatic hematology analyzer.
Statistical analysis
Data are presented as median and ranges. All the statistical
evaluations were performed by Mann–Whitney U test. The
correlations between parameters were measured with
Spearman rank test. The results were considered significant
when P \ 0.05.
Results
VEGF plasma concentration was significantly higher in AD
patients than in the healthy controls (31.2 and 17.2 pg/ml,
respectively; P = 0.0007; Fig. 1). Plasma concentrations
of VEGF-R1 and VEGF-R2 did not differ significantly
between AD patients and healthy subjects (36.2 vs 35.8 and
8,145 vs 7,470 pg/ml, respectively). There were no sig-
nificant differences in plasma concentrations of VEGF,
sVEGF-R1 and sVEGF-R2 between AD patients with and
without persistent allergic rhinitis. Plasma concentration of
PF-4 was significantly increased in AD patients as com-
pared with the controls (5.5 and 3.2 IU/ml, respectively,
P = 0.0005; Fig. 2). No significant correlation was found
between VEGF and PF-4 (r = 0.26, P = 0.6). There were
no correlations between VEGF and VEGF-R1 or VEGF-R2
or between VEGF-R1 and VEGF-R2. In addition, no
significant correlation was found between VEGF concen-
tration and the counts of platelets and eosinophils (data not
shown). Neither did we observe any significant correlation
between plasma VEGF and serum concentration of total
IgE and specific IgE anti-HDM (data not shown).
Plasma VEGF concentration did not correlate signifi-
cantly with EASI.
Discussion
These findings demonstrate for the first time that patients
with AD may show significantly increased plasma con-
centration of VEGF. Because platelets are important
sources of VEGF in the circulation [10, 11], we performed
the analysis in PPP. At present, the major sources and the
role of increased plasma concentration of VEGF in AD
patients are unknown and remain speculative.
Different cells involved in the pathogenesis of AD are
able to synthesize and release VEGF.
Overproduction of VEGF in AD lesional keratinocytes
has been demonstrated. The amount of VEGF produced in
the lesions of AD was approximately 25 times higher than
in normal stratum corneum; however, the mechanism is
unclear [6]. It is therefore possible that keratinocytes in AD















Fig. 1 Plasma VEGF concentration was significantly higher in AD















Fig. 2 Plasma PF-4 concentration was significantly higher in AD
patients as compared with controls (P = 0.0005)
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could contribute to the subsequent increase in plasma
concentration. Another important storage site is formed by
the platelets, which release VEGF upon activation in vivo.
It has been reported that platelet activation measured by
plasma concentrations of PF-4 and beta-thromboglobulin is
increased in AD patients [12–15], but not in other mani-
festations of atopic diathesis [16, 17]. In addition, it has
been suggested that chemokines are markers of AD
severity [13]. Our study indicated no significant correlation
between plasma concentrations of VEGF and PF-4, sug-
gesting that platelets are not likely to be the sole source of
VEGF in AD. It has been demonstrated that activated
eosinophils may appear to be an important source of the
vascular permeability factor, which may contribute to tis-
sue edema at the sites of allergic inflammation [18]. In
addition, sVEGFR1 is expressed by eosinophil whose
activation with VEGF stimulates directed migration and
activation of eosinophil. Thus, VEGF may play an
important role in the modulation of eosinophilic inflam-
mation [19]. In our study, there was no significant
correlation between plasma concentration of VEGF and
eosinophil counts, suggesting that eosinophils could not be
the sole source of VEGF in AD.
Other possible sources of VEGF include mast cells.
Mast cells can secrete VEGF and such secretion is
enhanced via upregulation of IgE receptor on mast cells
[20]. Interestingly, it has been suggested that transfer of
IgE from the circulating blood to extravascular tissue via
endothelial cells may depend on the concentration of
VEGF secreted from mast cells [21]. We did not observe
any significant correlation between plasma VEGF and
serum concentration of total IgE and specific IgE anti-
HDM. Furthermore, other cells involved in immune
inflammatory processes in AD can release VEGF. Different
cell sources probably contribute to the subsequent increase
in plasma concentration of VEGF.
Our results show that AD severity according EASI does
not correlate with plasma VEGF concentration. This might
suggest the lack of an important link between the degree of
skin inflammation and VEGF release. VEGF plasma con-
centration may not be a useful marker of disease severity.
It has been suggested that VEGF may play a role in the
pathogenesis of AD and may regulate the development of
AD lesions, acting possibly in the persisting erythema and
edema by prolonged capillary dilatation and hyperperme-
ability [6]. Apart from AD, increased expression of VEGF
has been observed in patients suffering from other inflam-
matory skin diseases associated with enhanced vascularity
and vascular hyperpermeability, including bullous pem-
phigoid, dermatitis herpetiformis and erythema multiforme
[22]. Overexpression of VEGF and its receptors has been
observed in delayed hypersensitivity skin reactions [23].
The significance of the increased concentration of cir-
culating VEGF in AD is unclear. Whether circulating
VEGF contributes directly or indirectly to AD pathogenesis
or is merely a secondary phenomenon needs to be deter-
mined. Because VEGF is a multifunctional cytokine
secreted by a variety of cells and is overexpressed in AD, it
leads to the hypothesis that circulating VEGF may be
involved in AD and provides a link between vascular
permeability and leukocyte recruitment as well as activa-
tion at sites of the inflammation.
There was no correlation between plasma concentrations
of VEGF and its soluble receptors (sVEGF-R1 and
sVEGF-R2) in AD patients.
Considering that sVEGF-R1 is a negative regulator of
VEGF availability (by sequestrating the ligand and by
forming inactive heterodimers with membrane-bound
VEGF receptors), one could expect some changes in
plasma sVEGF-R1 concentration shown by AD patients.
No increased plasma sVEGF-R1 concentration observed in
this study may suggest a paradoxical response of sVEGF-
R1, promoting the VEGF performance. Such a phenome-
non could hypothetically account for the disturbance of
mechanisms responsible for VEGF activity in the VEGF/
sVEGF-R1 system in AD patients. Our results are not
sufficient, however, to draw any ultimate conclusions,
particularly because data illustrating a correlation between
the concentration of VEGF and its receptors are scarce, if
not divergent.
On the other hand, the function of sVEGF-R2 is less
recognized, while in vitro it appears as a weak antagonist
of VEGF [24].
Conclusions
The study appears as the first reported evidence of an
increased concentration of VEGF in PPP in atopic der-
matitis; however, its role remains uncertain and further
investigations should be undertaken for better recognition
of its function. The involvement of VEGF in the inflam-
matory reaction of AD might be supported by evidence of a
variety of biological effects exerted by VEGF on cells and
processes that play a major role in AD. Different cells
sources probably contribute to the subsequent increase in
plasma concentration of VEGF. The major source of cir-
culating VEGF in AD is still unknown. It seems that
plasma VEGF concentration is not a useful marker of
disease severity and, apart from platelets, other cells might
also release the cytokine.
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